Srdjan Stankovic, MD, MSPH

Safety Profile of Adjunctive Pimavanserin in the ENHANCE Study, a Phase 3 Trial for the Potential Treatment of Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment

10/27/2020

Many patients with schizophrenia do not respond fully to antipsychotic treatment despite adherence. Evidence supporting polypharmacy is limited and adding another antipsychotic is associa...

Dragana Bugarski-Kirola , MD, MBA, MSc;

Response to Pimavanserin Treatment in Patients With Dementia-related Psychosis: Results From the 12-Week, Open-label Phase of the HARMONY Study

I-Yuan Liu , MSc;

Rene Nunez , MD;

Ramzey Odetalla , PA, MSc;

Mohammed Bari , MD;

Istvan Bitter , MD, PhD, DSc;

Peter Feldman , PhD;

10/08/2020

Dementia-related psychosis (DRP) is common in patients with Alzheimer‚Äôs disease (AD), dementia with Lewy bodies (DLB), Parkinson‚Äôs disease dementia (PDD), vascular dementia (VaD), and...

Pimavanserin Significantly Reduces Risk of Relapse of Dementia-related Psychosis: Results From the Double-Blind Phase of the HARMONY Study

Erin Foff , MD, PhD;

Davangere Devanand , MBBS, MD;

Clive Ballard , MBChB;

Bradley McEvoy , DrPH, MSc;

10/08/2020

Patients with dementia often experience dementia-related psychosis (DRP), which is associated with adverse outcomes and has no approved therapy in the US. Pimavanserin is a selective sero...

Effect of Adjunctive Pimavanserin on Insomnia and Function in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY

Erin Foff , MD, PhD;

Bradley McEvoy , DrPH, MSc;

Jeff Cummings , MD, ScD;

Maria-Eugenia Soto-Martin , MD;

Pierre Tariot , MD;

10/08/2020

Up to 90% of patients with major depressive disorder (MDD) experience sleep disturbances. CLARITY was a phase 2 study of adjunctive pimavanserin, a 5-hydroxytryptamine2A antagonist/invers...

Michael Thase , MD;

Richard Shelton , MD;

Keith Liu , PhD;

Susan Legacy , MD;

Manish Jha ;

Marlene Freeman , MD;

Madhukar Trivedi , MD;

George Papakostas , MD;

ADVANCE: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Negative Symptoms of Schizophrenia

10/08/2020

Pimavanserin is a selective, 5-hydroxytryptamine (5-HT)2A receptor inverse agonist/antagonist with lower activity at 5-HT2C receptors. Previous studies have shown beneficial effects of ad...

Dragana Bugarski-Kirola , MD, MBA, MSc;

Celso Arango , MD, PhD;

Henry Nasrallah , MD;

I-Yuan Liu , MSc;

Brandon Abbs , PhD;

Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder With Adjunctive Pimavanserin

10/08/2020

Sexual dysfunction occurs in 40%-60% of patients with major depressive disorder (MDD), due to either the illness itself and/or the effects of antidepressant treatment. The phase-2 CLARITY...

Michael Thase , MD;

Richard Shelton , MD;

Keith Liu , PhD;

Manish Jha ;

Marlene Freeman , MD;

George Papakostas , MD;

A Post Hoc Analysis Evaluating the Impact of a Reduction in Psychosis on the Severity of Agitation and Aggression in Patients With Alzheimer’s Disease

Madhukar Trivedi , MD;

11/22/2019

This post hoc analysis evaluates whether improvement in hallucinations and delusions during pimavanserin (PIM) treatment among Alzheimer’s dementia (AD) patients with psychosis leads to i...

Bruce Coate , MPH;

Michael Guskey , PharmD;

CLARITY: A Phase 2 Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder

Clive Ballard , MBChB;

11/22/2019

This study examined pimavanserin (PIM), a 5-HT2A receptor inverse agonist/antagonist, as a potential adjunct to SSRIs or SNRIs for major depressive disorder (MDD). Adult female and male p...

Michael Thase , MD;

Richard Shelton , MD;

Keith Liu , PhD;

Susan Legacy , MD;

Marlene Freeman , MD;

George Papakostas , MD;

Madhukar Trivedi , MD;

Exposure-Response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder

11/22/2019

Pimavanserin, a selective serotonin inverse agonist/antagonist at the 5-HT2A/C receptors, is being actively studied for multiple indications. The CLARITY clinical trial program is evaluat...

Julie Passarell , MA;

Becky Howell , MA, MBA;

Joel Owen , PhD;

Mona Darwish , PhD;